Evidence mapPaperPMID 38732018Full record

ArticleInternational journal of molecular sciences2024

Hydroxytyrosol, a Promising Supplement in the Management of Human Stroke: An Exploratory Study.

Ángela Naranjo, M Josefa Álvarez-Soria, Pilar Aranda-Villalobos, Ana M Martínez-Rodríguez, Esther Martínez-Lara, Eva Siles

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ángela NaranjoDepartamento de Biología Experimental, Universidad de Jaén, 23071 Jaén, Spain.ORCID 0000-0003-1419-2042
M Josefa Álvarez-SoriaServicio de Neurología, Hospital Universitario de Jaén, 23009 Jaén, Spain.
Pilar Aranda-VillalobosUGC Medicina Física y Rehabilitación, Hospital Universitario de Jaén, 23009 Jaén, Spain.ORCID 0000-0001-7426-7646
Ana M Martínez-RodríguezDepartamento de Estadística e Investigación Operativa, Universidad de Jaén, 23071 Jaén, Spain.ORCID 0000-0002-7609-5611
Esther Martínez-LaraDepartamento de Biología Experimental, Universidad de Jaén, 23071 Jaén, Spain.
Eva SilesDepartamento de Biología Experimental, Universidad de Jaén, 23071 Jaén, Spain.ORCID 0000-0003-4192-7008

Funding

Programa Operativo FEDER Andalucía 2014/2020 1380831
6 · The paper itself

Abstract

Hydroxytyrosol (HT) is a bioactive olive oil phenol with beneficial effects in a number of pathological situations. We have previously demonstrated that an HT-enriched diet could serve as a beneficial therapeutic approach to attenuate ischemic-stroke-associated damage in mice. Our exploratory pilot study examined this effect in humans. Particularly, a nutritional supplement containing 15 mg of HT/day was administered to patients 24 h after the onset of stroke, for 45 days. Biochemical and oxidative-stress-related parameters, blood pressure levels, serum proteome, and neurological and functional outcomes were evaluated at 45 and 90 days and compared to a control group. The main findings were that the daily administration of HT after stroke could: (i) favor the decrease in the percentage of glycated hemoglobin and diastolic blood pressure, (ii) control the increase in nitric oxide and exert a plausible protective effect in oxidative stress, (iii) modulate the evolution of the serum proteome and, particularly, the expression of apolipoproteins, and (iv) be beneficial for certain neurological and functional outcomes. Although a larger trial is necessary, this study suggests that HT could be a beneficial nutritional complement in the management of human stroke.

Indexed as

Dietary SupplementsOxidative StressPhenylethyl AlcoholStrokeAgedBlood PressureFemaleHumansMaleMiddle AgedNitric OxidePilot Projects3,4-dihydroxyphenylethanolNitric OxidePhenylethyl Alcoholblood pressureHbA₁chydroxytyrosolischemic strokelipid profileneurological and functional outcomesoxidative-stress-related markersproteomics

Identifiers

PMID38732018
PMCPMC11084205

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.